Abstract: The present invention relates to a therapeutic polypeptide and methods for its creation and use for modulating an immune response in a host organism in need thereof. In particular, the invention relates to the administration to an organism in need thereof, of an effective amount of a pre-coupled polypeptide complex comprising a lymphokine polypeptide portion, for example IL-15 (SEQ ID NO: 5, 6), IL-2 (SEQ ID NO: 10, 12) or combinations of both, and an interleukin receptor polypeptide portion, for example IL-15Ra (SEQ ID NO: 7, 8), IL-2Ra (SEQ ID NO: 9, 11) or combinations of both, for augmenting the immune system in, for example, cancer, SCID, AIDS, or vaccination; or inhibiting the immune system in, for example, rheumatoid arthritis, or Lupus. The therapeutic complex of the invention surprisingly demonstrates increased half-life, and efficacy in vivo.
Abstract: A modified DNA, polymerase belonging to family B that is not inhibited by dUTP is provided. The modified DNA polymerase comprises modifications of at least two amino acids selected from the group consisting of amino acids corresponding to Y7, P36, and V93 in SEQ ID NO: 1, in the amino acid sequence represented by any one of SEQ ID NOs: 1 to 10.
Abstract: Compositions for modulating the expression of a protein in a target cell comprising at least one RNA molecule which comprises at least one modification 5 conferring stability to the RNA, as well as related methods, are disclosed.
Type:
Grant
Filed:
May 18, 2015
Date of Patent:
May 1, 2018
Assignee:
TRANSLATE BIO, INC.
Inventors:
Braydon Charles Guild, Michael Heartlein, Frank DeRosa
Abstract: Inflammatory and other cellular response-modulating compositions are provided comprising aminoacyl-tRNA synthetase polypeptides, including active fragments and/or variants thereof. Also provided are methods of using such compositions in the treatment of conditions that benefit from the modulation of inflammation, such as inflammatory diseases or conditions.
Type:
Grant
Filed:
November 30, 2016
Date of Patent:
April 17, 2018
Assignee:
aTyr Pharma, Inc.
Inventors:
Jeffry Dean Watkins, Alain Philippe Vasserot, Leslie Ann Greene, Ryan Andrew Adams, Kyle P. Chiang, Wei Zhang, Kristi Helen Piehl, Fei Hong, Alina He
Abstract: Methods are disclosed for use of apatite chromatography, particularly without reliance upon phosphate gradients, for purification or separation of at least one intact non-aggregated antibody, or at least one immunoreactive antibody fragment, from an impure preparation. Integration of such methods into multi-step procedures with other fractionation methods are additionally disclosed.
Abstract: The present invention is directed to a method for detecting an interaction between a ribonucleic acid (RNA) molecule and a second molecule. This method involves providing a nucleic acid construct that contains a promoter sequence, a nucleotide sequence encoding the RNA molecule, and an RNA polymerase blocking site. The nucleotide sequence encoding the RNA molecule is transcribed in vitro to produce an RNA transcript corresponding to the RNA molecule. Transcription is halted by the RNA polymerase blocking site under conditions effective for the RNA transcript to remain tethered to the nucleic acid construct. The tethered RNA transcript is contacted with the second molecule and any interaction between the tethered RNA transcript and the second molecule is detecting and identified based on said contacting.
Type:
Grant
Filed:
June 15, 2013
Date of Patent:
April 10, 2018
Assignee:
Cornell University
Inventors:
John T. Lis, Abdullah Ozer, Jacob M. Tome
Abstract: The present invention provides a method of designing an optimized gene which comprises altering a nucleotide sequence of a target protein gene, so that only preferential codons with high frequency of use in human cells are selected and a GC content of not less than 60% is achieved. A gene design method which involves the feature “only preferential codons with high frequency of use are selected and a GC content of not less than 60% is achieved” can be established as a general rule for preparing proteins with high expression level, in order to obtain chemically synthesized genes for proteins capable of high-level expression in eukaryotes.
Abstract: The present invention provides isolated polypeptides isolatable from a Staphylococcus spp. Also provided by the present invention are compositions that include one or more of the polypeptides, and methods for making and methods for using the polypeptides.
Abstract: A bioconversion method of making vanillin including expressing VaoA gene in a mixture, expressing MtSAD1 gene in the mixture, feeding eugenol to the mixture, and converting ferulic acid to vanillin by incubating with a microbial Amycolatopsis sp. strain (Zhp06) and/or a recombinant E. coli strain.
Abstract: The present invention relates to the modification of lignin biosynthesis in plants and, more particularly, to enzymes involved in the lignin biosynthetic pathway and nucleic acids encoding such enzymes.
Type:
Grant
Filed:
December 10, 2014
Date of Patent:
April 3, 2018
Assignees:
Dairy Australia Limited, Agriculture Victoria Services PTY LTD
Inventors:
German Carlos Spangenberg, Angela Jane Lidgett, Robyn Louise Heath, Russell Leigh McInnes, Damian Paul Lynch, Ulrik John, Aidyn Mouradov
Abstract: The invention provides compositions and methods for inhibiting the expression of the gene Snl6 in plants. Plants with inhibited expression of Snl6 have use in biofuel production, e.g., by increasing the amount of soluble sugar that can be extracted from the plant.
Type:
Grant
Filed:
June 17, 2011
Date of Patent:
April 3, 2018
Assignee:
The Regents of the University of California
Inventors:
Rebecca Bart, Mawsheng Chern, Pamela Ronald, Miguel Vega-Sanchez
Abstract: The invention relates to a process for parallel high throughput sequencing of nucleic acid molecules, in particular in the single molecule format.
Abstract: A formulation is provided for application to a host plant to reduce, inhibit or impair one or more of growth and development of the host plant. A method of inhibiting growth plant growth and development is also provided as a means of controlling weedy species. The method comprises: selecting a suitable gene for growth suppression in a target plant; identifying an at least one target site accessible to base pairing in the suitable gene; identifying an at least one divergent site in the at least one target site; designing a construct complementary to the at least one divergent site; adding an at least one RNAi inducer to the construct; and delivering the construct to the target plant.
Abstract: Methods of treating glycogen storage disease type II, by administering acid ?-glucosidase, are described, as are compositions for use in treatment of glycogen storage disease type II.
Abstract: The present invention relates to alpha-amylase variants. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.
Abstract: Described herein, inter alia, are compositions, oleagnious organisms, and methods useful for producing lipids, lipid precursors, and/or oleochemicals.
Type:
Grant
Filed:
May 2, 2014
Date of Patent:
February 20, 2018
Assignee:
Board of Regents, The University of Texas System
Inventors:
John Blazeck, Andrew Hill, Leqian Liu, Hal Alper
Abstract: The present invention is directed to compositions and methods of delivery of CoQ that is reduced in the presence of lipoic acid and, optionally a fatty acid and/or optionally in a monoterpene. The compositions that include the reduced CoQ can be formulated in soft gel capsules.
Abstract: Described herein are polynucleotides associated with prostate and lung cancer. The polynucleotides are miRNAs and miRNA precursors. Related methods and compositions that can be used for diagnosis, prognosis, and treatment of those medical conditions are disclosed. Also described herein are methods that can be used to identify modulators of prostate and lung cancer.
Type:
Grant
Filed:
May 4, 2017
Date of Patent:
February 13, 2018
Assignee:
ROSETTA GENOMICS LTD.
Inventors:
Itzhak Bentwich, Amir Avniel, Yael Karov, Ranit Aharonov
Abstract: The present compositions and methods relate to a beta-mannanase from Bacillus hemicellulosilyticus, polynucleotides encoding the beta-mannanase, and methods of make and/or use thereof. Formulations containing the beta-mannanase are suitable for use in hydrolyzing lignocellulosic biomass substrates, especially those comprising a measurable level of galactoglucomannan (GGM) and/or glucomannan (GM).
Type:
Grant
Filed:
December 2, 2013
Date of Patent:
January 30, 2018
Assignee:
DANISCO US INC.
Inventors:
Ling Hua, Rosalyn Lau, Steven Le, Zhen Qian, Zheyong Yu
Abstract: The present invention relates to polypeptides having glucoamylase activity and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.
Type:
Grant
Filed:
July 2, 2015
Date of Patent:
January 23, 2018
Assignees:
NOVOZYMES A/S, NOVOZYMES NORTH AMERICA, INC.
Inventors:
Sara Landvik, Marc Dominique Morant, Keiichi Ayabe, Guillermo Coward-Kelly
Abstract: This invention provides compositions and methods for producing translational components that expand the number of genetically encoded amino acids in vertebrate cells. The components include orthogonal tRNA's, orthogonal aminoacyl-tRNA synthetases, orthogonal pairs of tRNA's/synthetases and unnatural amino acids. Proteins and methods of producing proteins with unnatural amino acids in vertebrate cells are also provided. The present invention provides vertebrate cells with translation components, e.g., pairs of orthogonal aminoacyl-tRNA synthetases (O-RSs) and orthogonal tRNA's (O-tRNA's) and individual components thereof, that are used in vertebrate protein biosynthetic machinery to incorporate an unnatural amino acid in a growing polypeptide chain, in a vertebrate cell.
Abstract: An inhibitor targeting specific complement, the inhibitor targeting specific complement is a protein, the protein has a targeted inhibition function on the complement activation, and the amino acid sequence of the protein comprises CRIg extracellular domain and complement inhibiting domain; the amino acid sequence of the protein is consist of the CRIg extracellular domain and the complement inhibiting domain connected directly, or indirectly through a linker which can connect the two domains. The preparation method of the inhibitor targeting specific complement comprises connecting the protein polypeptides of the CRIg extracellular domain and the complement inhibiting domain by gene engineering technology. The protein can be used to prepare a drug targeting inhibition of complement activation.
Abstract: The present invention relates to variants (mutants) of polypeptides, in particular Termamyl-like alpha-amylases, which variant has alpha-amylase activity and exhibits an alteration in at least one of the following properties relative to said parent alpha-amylase: substrate specificity, substrate binding, substrate cleavage pattern, thermal stability, pH/activity profile, pH/stability profile, stability towards oxidation, Ca2+ dependency, specific activity, and solubility, in particular under production conditions.
Abstract: Described herein are compositions comprising at least one auxin transport inhibitor for pre-treating a plant or seed to increase saccharification, or saccharide release by hydrolysis, the at least one auxin transport inhibitor being in an amount effective to increase sugar release from a plant tissue by hydrolysis. Also described are plant mutations, and methods to screen for such plant mutations, having an improved sugar release phenotype. The described compositions, methods and plant mutations are particularly useful for producing biofuel crops, such as maize, to improve sugar extractability from lignocellulosic biomass and hence, the efficiency of bioethanol production overall.
Type:
Grant
Filed:
March 26, 2013
Date of Patent:
January 2, 2018
Assignee:
THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO
Inventors:
Dario Torquato Bonetta, Peter John McCourt, Danielle Vidaurre, George Stamatiou
Abstract: The described invention provides a method of treating a patient with an epithelial cancer comprising administering a composition comprising a therapeutic amount of an inhibitor of a BTK protein and one or more chemotherapeutic agent(s) selected from the group consisting of an antimetabolite, a platinum coordination compound, an alkylating agent and a combination thereof, wherein the composition is effective to reduce one or more of tumor cell growth, tumor cell clonogenicity, tumor cell proliferation, tumor cell viability and tumor volume and the therapeutic amount of the inhibitor of a BTK protein and the one or more chemotherapeutic agent(s) exerts a synergistic effect. The described invention also provides methods of treating a chemotherapy drug-resistant cancer and sensitizing a cancer patient to chemotherapy.
Type:
Grant
Filed:
December 30, 2014
Date of Patent:
November 21, 2017
Assignee:
Bionsil S.R.L. in Liquidazione
Inventors:
Marialuisa Lavitrano, Emanuela Grassilli, Kristian Helin
Abstract: Methods of recovering plant-derived proteins or suprastructure proteins, are provided. The method may comprise obtaining a plant, or plant matter comprising apoplast-localized proteins, or suprastructure proteins, loosening the cell wall to produce a plant or plant matter having a loosened cell wall, thus allowing the release of apoplastic content through the cell wall to produce an apoplastic content fraction from the plant or plant matter, and recovering the apoplastic content fraction. The apoplastic content fraction comprises plant-derived proteins or suprastructure proteins.
Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.
Type:
Grant
Filed:
May 12, 2017
Date of Patent:
October 17, 2017
Assignee:
Silence Therapeutics GMBH
Inventors:
Klaus Giese, Jörg Kaufmann, Anke Klippel-Giese
Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.
Type:
Grant
Filed:
May 8, 2017
Date of Patent:
October 17, 2017
Assignee:
Silence Therapeutics GMBH
Inventors:
Klaus Giese, Jörg Kaufmann, Anke Klippel-Giese
Abstract: The invention relates to compositions and methods for the design, evolution, preparation, and/or manufacture of enzymes for use with polynucleotides, primary transcripts and mmRNA molecules.
Type:
Grant
Filed:
November 18, 2016
Date of Patent:
October 17, 2017
Assignee:
ModernaTX, Inc.
Inventors:
Yuxun Wang, Divakar Ramakrishnan, Antonin De Fougerolles, Susan Whoriskey
Abstract: Compositions comprising one or more compounds expressed by fetal tissues for modulating skin conditions, methods of identifying the compounds, and methods of making and using the compounds are provided.
Type:
Grant
Filed:
October 30, 2007
Date of Patent:
October 10, 2017
Assignee:
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Abstract: The present invention is directed to plants that display an improved oil quantity phenotype or an improved meal quality phenotype due to altered expression of an HIO nucleic acid. The invention is further directed to methods of generating plants with an improved oil quantity phenotype or improved meal quality phenotype.
Type:
Grant
Filed:
November 14, 2014
Date of Patent:
September 19, 2017
Assignee:
Dow AgroSciences LLC.
Inventors:
John P. Davies, Hein Tsoeng (Medard) Ng
Abstract: The present invention relates to isolated polypeptides having cellulolytic enhancing activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.
Type:
Grant
Filed:
October 20, 2014
Date of Patent:
September 19, 2017
Assignees:
Novozymes A/S, Novozymes, Inc.
Inventors:
Lan Tang, Ye Liu, Junxin Duan, Wenping Wu, Randall Kramer
Abstract: The present invention relates to variant thioesterases and their use in plants, e.g., to increase enzymatic activity and to promote increased production of mid-chain length fatty acids (e.g., 8 to 14 carbons) and at desired ratios. Further disclosed herein are methods of manufacturing renewable chemicals through the manufacture of novel triglyceride oils followed by chemical modification of the oils. Oils containing fatty acid chain lengths of C8, C10, C12 or C14 are also disclosed and are useful as feedstocks in the methods described herein.
Type:
Grant
Filed:
July 24, 2015
Date of Patent:
September 19, 2017
Assignee:
TERRAVIA HOLDINGS, INC.
Inventors:
David Davis, Scott Franklin, Jeffrey L. Moseley, Riyaz Bhat
Abstract: The present invention relates to glucoamylase variants having improved thermostability. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.
Type:
Grant
Filed:
November 29, 2016
Date of Patent:
September 19, 2017
Assignee:
NOVOZYMES A/S
Inventors:
Esben Peter Friis, Leonardo De Maria, Jesper Vind, Thomas A. Poulsen, Allan Svendsen, Steffen Danielsen, Rolf T. Lenhard, Henrik Friis-Madsen, Lars K. Skov
Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.
Type:
Grant
Filed:
May 8, 2017
Date of Patent:
September 12, 2017
Assignee:
Silence Therapeutics GMBH
Inventors:
Klaus Giese, Jörg Kaufmann, Anke Klippel-Giese
Abstract: The present invention relates to novel polypeptides derived from endolysins from a bacteriophage of Clostridium perfringens and to nucleic acid molecules encoding the same, as well as compositions thereof. The invention also provides uses of such polypeptides and nucleic acid molecules in the diagnosis and treatment of conditions and diseases associated with microbial cells such as Clostridium perfringens. In particular, the invention provides a polypeptide having endolysin activity derived from bacteriophage ?CP51 of Clostridium perfringens and uses thereof.
Abstract: The disclosure provides methods of engineering plants to modulate galactan content. Specifically, the disclosure provides methods for engineering a plant to increase the galactan content in a plant tissue by inducing expression of beta-1,4-galactan synthase (GALS), modulated by a heterologous promoter. Further disclosed are the methods of modulating expression level of GALS under the regulation of a transcription factor, as well as overexpression of UDP-galactose epimerse in the same plant tissue. Tissue specific promoters and transcription factors can be used in the methods are also provided.
Type:
Grant
Filed:
May 10, 2013
Date of Patent:
August 22, 2017
Assignee:
The Regents of the University of California
Inventors:
Henrik Vibe Scheller, Joshua L. Heazlewood
Abstract: A target protein is prepared as soluble protein using a recombinant protein expression system. An expression vector is used that includes (1) an expression-inducible promoter sequence; (2) a first coding sequence including a polynucleotide coding for a polypeptide that is represented by the formula (Z)n; and (3) a second coding sequence that includes a polynucleotide that codes for a target protein. A method of producing the target protein is also used that includes expressing protein using this expression vector.
Abstract: Described are compositions and methods relating to variant filamentous fungi having altered growth characteristics. Such variants are well-suited for growth in submerged cultures, e.g., for the large-scale production of enzymes and other proteins for commercial applications.
Type:
Grant
Filed:
April 20, 2012
Date of Patent:
August 8, 2017
Assignee:
DANISCO US INC
Inventors:
Elizabeth A. Bodie, Robert James Pratt, II
Abstract: The present disclosure pertains to methods of producing recombinant peptides that contain between 10 and 200 amino acid residues using novel carrier proteins derived from superfolder green fluorescent protein and its mutants.
Abstract: The present invention provides a method of producing patchoulol and 7-epi-?-selinene, said method comprising contacting at least one polypeptide with famesyl phyrophosphate (FPP). In particular, said method may be carried out in vitro or in vivo to produce patchoulol and 7-epi-?-seline, compounds which can be useful in the field of perfumery. The present invention also provides the amino acid sequence of polypeptide useful in the method of the invention. A nucleic acid encoding the polypeptide of the invention and an expression vector containing said nucleic acid are also part of the present invention. A non-human host organism or a cell transformed to be used in the method of producing patchoul and 7-epi-?-selinene is also an object of the present invention.
Abstract: The present invention discloses Hemipteran insect inhibitory proteins, methods of using such proteins, nucleotide sequences encoding such proteins, methods of detecting and isolating such proteins, and their use in agricultural systems.
Type:
Grant
Filed:
February 4, 2016
Date of Patent:
July 25, 2017
Assignee:
Monsanto Technology LLC
Inventors:
James A. Baum, Artem G. Evdokimov, Farhad Moshiri, Timothy J. Rydel, Eric J. Sturman, Moritz von Rechenberg, Halong Vu, Andrew M. Wollacott, Meiying Zheng
Abstract: In one aspect, the invention is directed to polypeptides having an amylase activity, polynucleotides encoding the polypeptides, and methods for making and using these polynucleotides and polypeptides. In one aspect, the polypeptides of the invention can be used as amylases, for example, alpha amylases, to catalyze the hydrolysis of starch into sugars.
Type:
Grant
Filed:
May 22, 2015
Date of Patent:
July 11, 2017
Assignee:
BASF Enzymes LLC
Inventors:
Walter Callen, Toby Richardson, Gerhard Frey, Carl A. Miller, Martin Kazaoka, Eric J. Mathur, Jay M. Short
Abstract: The present invention relates to novel mutants of Streptokinase, its functional fragments and covalently modified forms. Methods are provided for the preparation of the bacterial plasminogen activator protein, Streptokinase its muteins, species variants and their covalently modified variants that are characterized by improved therapeutic properties, such as increased proteolytic stability, extended plasma half-lives, reduced immuno-reactivity and enhanced fibrin clot specificity. The method involves either incorporating additional cysteine residues, or substituting cysteine residues for naturally occurring amino acids into non-essential regions of the protein such that the catalytic activity of the resultant protein remains largely unaltered. These cysteine variants were further modified by covalently attaching a cysteine reactive polymer such as polyethylene glycol (PEG) or sulfhydryl-reactive moieties from a group that includes fluorophore, spin labels or other small conjugates.
Type:
Grant
Filed:
August 19, 2015
Date of Patent:
July 4, 2017
Assignee:
COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH
Abstract: Provided herein are compositions and methods useful for reducing glucose inhibition in transporting xylose, arabinose and other monosaccharides, into a yeast cell.
Type:
Grant
Filed:
May 21, 2015
Date of Patent:
July 4, 2017
Assignee:
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
Abstract: The present invention relates to variants of a parent alpha-amylase, the variant having improved stability or activity at low calcium conditions or at low pH.
Abstract: The present invention relates to a time-temperature indicator system useful for monitoring the time and temperature exposure of foods, nutraceuticals, pharmaceuticals, cosmetics, chemicals and other products. The system provides improved time-temperature sensitivity, time-temperature sensitivity control and a response which better reflects that of the reactions leading to quality loss of the monitored product. Further, the invention also relates to a combination comprising a time-temperature indicator system and a product storage container or a bag closure device. A method for producing said time-temperature indicator system is also part of the present invention.
Type:
Grant
Filed:
April 10, 2012
Date of Patent:
June 27, 2017
Assignee:
Keep-It Technologies AS
Inventors:
Åsmund K. Røhr, Peder Oscar Andersen, Brit Salbu, Eggert F. Gudjonsson, Marit Nandrup Pettersen, Christian Salbu Aasland
Abstract: The present invention relates to cleaning compositions comprising variants of an alpha-amylase and methods of treating surfaces such as textiles with aqueous liquor comprising such compositions, especially at low temperatures.
Type:
Grant
Filed:
February 3, 2016
Date of Patent:
June 6, 2017
Assignee:
The Procter & Gamble Company
Inventors:
Michelle Jackson, Philip Frank Souter, Lindsay Suzanne Bewick, Svend Kaasgaard, Jens Oebro, Signe Eskildsen Larsen, Allan Svendsen, Annette Helle Johansen, Michael Skjoet, Carsten Andersen, Lars Beier, Esben Peter Friis, Miguel Duarte Guilherme Pereira Toscano, Mads Bjoernvad, Frank Winther Rasmussen, Liv Spaangner Christiansen
Abstract: Disclosed herein is a recombinant Bacillus manganese oxidase complex, including a bacterial expression vector for the expression of the complex and a method of synthesizing the complex.